Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $55.00

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective increased by analysts at Barclays from $39.00 to $55.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Barclays‘s target price suggests a potential upside of 25.00% from the company’s current price.

TNDM has been the subject of a number of other reports. SVB Leerink raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and increased their price target for the company from $34.00 to $45.00 in a research note on Thursday, April 25th. Robert W. Baird boosted their price target on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Stifel Nicolaus upped their price target on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, April 23rd. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $44.00 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. The company has a fifty day moving average price of $32.91 and a two-hundred day moving average price of $26.53. Tandem Diabetes Care has a 12 month low of $13.82 and a 12 month high of $47.00. The company has a market cap of $2.84 billion, a PE ratio of -20.28 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The business had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Research analysts expect that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Several institutional investors have recently bought and sold shares of TNDM. MCF Advisors LLC raised its stake in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 445 shares in the last quarter. Van ECK Associates Corp grew its stake in Tandem Diabetes Care by 8.6% in the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after buying an additional 467 shares during the last quarter. Diversified Trust Co raised its holdings in Tandem Diabetes Care by 5.6% in the 4th quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock worth $313,000 after acquiring an additional 564 shares during the period. Raymond James & Associates raised its holdings in Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after acquiring an additional 737 shares during the period. Finally, Commonwealth Equity Services LLC lifted its position in Tandem Diabetes Care by 10.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock worth $205,000 after acquiring an additional 908 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.